Pharmaceutical compositions for the coordinated delivery of NSAIDs
The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.
1. A method of reducing the incidence of NSAID-associated gastric ulcers in a patient requiring NSAID treatment for osteoarthritis, rheumatoid arthritis, or ankylosing spondylitis, and who is at risk of developing an NSAID-associated ulcer, wherein the method comprises administering to said patient a therapeutically effective amount of a pharmaceutical composition in unit dosage form comprising:
(a) esomeprazole or a pharmaceutically acceptable salt thereof wherein, upon introduction of said unit dosage form into a medium, said esomeprazole or a pharmaceutically acceptable salt thereof is released regardless of the pH of the medium; and
(b) naproxen surrounded by coating that does not dissolve until the surrounding medium is at a pH of at least 3.5.
2. The method of claim 1 , wherein naproxen is surrounded by coating that does not dissolve until the surrounding medium is at a pH of at least 4.0.
3. The method of claim 1 , wherein naproxen is surrounded by coating that does not dissolve until the surrounding medium is at a pH of at least 5.0.
4. The method of claim 1 , wherein naproxen is present in said unit dosage form in an amount of 200-600 mg.
5. The method of claim 1 , wherein naproxen is present in said unit dosage form in an amount of 500 mg.
6. The method of claim 1 , wherein esomeprazole or a pharmaceutically acceptable salt thereof is present in said unit dosage form in an amount of from 5 to 100 mg.
7. The method of claim 1 , wherein naproxen is present in said unit dosage form in an amount of between 200-600 mg and esomeprazole or a pharmaceutically acceptable salt thereof in an amount of from 5 to 100 mg per unit dosage form.
8. The method of claim 1 , wherein said coating is a time-release coating.
9. The method of claim 1 , wherein said coating is a pH-responsive coating.